Shares of Hypermarcas (OTCMKTS:HYPMY - Get Free Report) gapped up prior to trading on Thursday . The stock had previously closed at $4.45, but opened at $4.60. Hypermarcas shares last traded at $4.39, with a volume of 533 shares.
Wall Street Analyst Weigh In
Separately, Scotiabank raised shares of Hypermarcas to a "strong-buy" rating in a research note on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat, Hypermarcas currently has an average rating of "Strong Buy".
View Our Latest Stock Report on HYPMY
Hypermarcas Stock Down 1.1%
The company has a market cap of $2.79 billion, a PE ratio of 20.95 and a beta of 0.86. The stock's 50 day moving average price is $4.43 and its 200-day moving average price is $4.21. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.80 and a current ratio of 1.26.
Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.12 earnings per share (EPS) for the quarter. Hypermarcas had a net margin of 11.28% and a return on equity of 6.19%.
Hypermarcas Company Profile
(
Get Free Report)
Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hypermarcas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hypermarcas wasn't on the list.
While Hypermarcas currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
